Chapter 12: Communicable & Infectious Disease Risks

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive, the only show that slices through stacks of research, dense textbook chapters, and expert analysis to give you the clearest, most relevant insights you need, fast.

Today we are cutting deep into a topic that is just fundamentally dynamic and always changing.

Communicable and infectious disease risks in community health nursing.

Exactly.

We're looking at a core public health challenge here.

We're exploring how diseases like HIV, STDs, and TB, well,

how they become resistant.

How new treatments completely change the game.

Right, and how global incidence rates are constantly shifting, you know, under the pressure of all social determinants.

Okay, so let's unpack this with a critical nursing lens.

We've synthesized a huge amount of material focusing on infectious disease control,

population health concepts, and of course, epidemiology.

So the mission here isn't just to define the diseases, is it?

No, not at all.

It's to define the risks, understand the really complex transmission routes, and most importantly, to lock down the tiered prevention strategies.

For some of the most persistent public health threats we face.

HIV, STDs, hepatitis, and tuberculosis.

For anyone practicing community or public health nursing, this knowledge is, I mean, it's the bedrock of your practice.

We're moving beyond just the bedside to look at population level strategies.

And this whole discussion is really framed by national priorities, isn't it?

Yeah.

Specifically,

the objectives laid out in Healthy People 2030.

That's exactly right.

And those objectives are exceptionally targeted.

I mean, they're demanding that we improve access to STI care, focusing heavily on vulnerable populations, you know, adolescents, LGBT individuals, while also emphasizing preventive care and widespread vaccination programs.

Precisely.

The core insight we want you to carry throughout this deep dive is that for the conditions we're reviewing today,

the vast majority are acquired through behaviors that can be altered or avoided.

Or through a lack of immunization efforts in the community.

Exactly.

So the nursing action, therefore, has to focus heavily on primary prevention.

Stopping the disease before it even starts.

And aggressive secondary prevention for rapid containment, if it does.

Okay.

That sets a very clear roadmap for us.

We're going to start by diving into the biological, social, and policy landscape that surrounds human immunodeficiency virus.

Then we'll move through specific sexually transmitted diseases.

And we'll pay close attention to the really crucial differences between bacterial and viral pathogens.

After that, we'll analyze the critical profiles of the various hepatitis viruses, and then tackle the global threat of tuberculosis.

And we'll wrap it all up with an extensive look at the specific tiered nursing roles in primary, secondary, and tertiary prevention, focusing on how nurses actually execute policies.

Things like contact tracing and directly observed therapy.

Exactly.

So let's get started with HIV.

When you look back at the history of HIV, you just have to acknowledge the enormous political and social shadow it cast, especially in the early decades.

It wasn't just a biological crisis.

It was a societal one.

The early controversies were, I mean, they were explosive.

The widespread fear, the intense stigma, and the outright discrimination.

It was particularly aimed at homosexuals and injection drug users, or IDUs.

Groups that were already pushed to the margins of society.

And you could argue that the societal response was, in the long run, just as damaging as the virus itself.

Because it just complicated the public health response so significantly.

I mean, think about the debates that raged over basic harm reduction methods.

Right.

Distributing clean needles.

Right.

Distributing clean needles to injection drug users.

To some policymakers, that wasn't seen as a life -saving public health intervention to stop a blood -borne pathogen.

They saw it as condoning drug use.

Exactly.

And this conflict, you know, between public health necessity and this kind of judgment, it severely hampered the early containment efforts.

And when a disease becomes chronic like this,

the financial implications are just.

They're staggering.

This chronicity means lifetime costs are enormous.

And that can push individuals into real economic distress.

That's such a critical point for population health planning.

Medicaid and Medicare, they end up supporting most of the health care delivery costs for people who are infected.

And why is that?

Simply because managing HIV often pushes people into indigence or poverty.

The medication costs are high.

There's the inability to work.

It all adds up.

Do we have hard numbers on that?

We do.

The estimated lifetime cost of care for a single client infected with HIV, and this is based on 2015 estimates, was around $326 ,500.

Over a quarter of a million dollars per person.

So as a case manager, how do community health nurses navigate that financial landscape for their clients, especially those in high prevalence areas?

We have to rely on some crucial funding mechanisms.

The most significant one is the Ryan White HIV AIDS program.

Which is authorized through the Ryan White HIV Treatment Extension Act?

Correct.

And this program specifically provides funds for health care, for support services, and for treatment adherence programs in the geographic areas with the largest number of AIDS cases.

And related to that, you have the AIDS Drug Assistance Programs or ADEPIs.

Right.

ADTs are state level programs, but they're funded by the federal government.

They get awards based on the estimated number of people living with AIDS in that specific state.

And they are crucial because they pay for those incredibly expensive, life -saving antiretroviral medications.

They're absolutely essential.

Without programs like Ryan White and the ADTs, adherence to heart or highly active antiretroviral therapy, it would just collapse because of financial barriers.

And that would lead to increased viral loads, progression to AIDS, and wider community transmission.

Exactly.

So these programs are vital case management tools for nurses who are trying to ensure that continuity of care.

Okay.

Let's move to the biology and look at the natural history of the virus.

So HIV is, at its core, a retrovirus that attacks the body's immune system.

Specifically, the CD4 T cells, which can eventually lead to Acquired Immunodeficiency Syndrome, or AIDS.

And while there's still no cure.

Modern medical advances, especially antiretroviral therapy, have really transformed it into a chronic controllable condition.

But for nurses, understanding the three distinct stages of its natural history is crucial for screening and counseling.

So stage one is the primary infection, the acute phase.

What's the biggest diagnostic hurdle here?

The biggest hurdle is, without a doubt, misdiagnosis.

This acute phase happens within about a month of contracting the virus.

And it often presents as a mononucleosis -like syndrome, right?

Fever, chills, rash.

Night sweats, profound fatigue.

And because those symptoms are so nonspecific and flu -like, they frequently go unrecognized.

By both the client and their doctor.

Yes.

And critically, during this time, the body's CD4 white blood cell count temporarily drops, and the standard antibody test, it's still negative.

And that initial negativity defines that treacherous window period.

Precisely.

The client is infectious, potentially transmitting the virus, but that standard antibody test is useless at this point.

This period lasts until the body develops enough antibodies.

Which brings us to stage two, clinical latency.

Right.

So the appearance of those detectable antibodies, we call it seroconversion, can take anywhere from six weeks up to three months after infection.

And that's when most screening tests will finally turn positive.

Correct.

And that marks the beginning of the clinical latency stage.

The client may be asymptomatic for many, many years, but they are infectious, and their immune system is in a state of gradual deterioration.

And that stage has been exponentially extended by heart.

Oh,

dramatically.

Highly active antiretroviral therapy has significantly increased survival time and quality of life.

Okay.

And then finally, stage three, AIDS,

the most severe phase.

A person is formally diagnosed with AIDS when their CD4 cell count drops below that critical threshold of 200 cells per cubic millimeter.

Or if they develop specific opportunistic infections.

Right.

And these opportunistic infections are basically diseases caused by common microorganisms that would be harmless in a healthy person.

But in a severely impaired immune system, they just, they take over.

They overwhelm it.

So what are the clinical signs that a public health nurse needs to be looking for as potential flags for progression to AIDS?

We look for the classic opportunistic infections.

The most common are pneumocystis, Giroveci pneumonia, or PJP, and oral candidiasis, which is thrush.

But you also see increased rates of pulmonary TB.

Yes.

And that can spread rapidly among immunosuppressed people in congregate settings, like shelters or correctional facilities, and unfortunately, invasive cervical cancer.

So this is why that careful screening for latent TB is absolutely mandated before admitting anyone with HIV to a long -term care facility.

It's a critical safety measure.

Let's shift our focus to transmission and epidemiology.

The source material clearly lists the transmission modes, but what's the crucial education piece for the community nurse here?

Well, the modes are what you'd expect.

Exposure to blood, semen, vaginal secretions, transplanted organs, and breast milk.

Okay.

But the crucial nursing role is in challenging misinformation and stigma.

The nurse has to be a role model and educate the community on what is not a transmission route.

Right.

So HIV is not transmitted through casual contact.

Not at all.

Not through touching, hugging, sharing an office kitchen.

It's also not transmitted by insects or coughing or sneezing.

And that clarity is essential to combat the stigma, which is still one of the biggest barriers to testing and treatment.

Absolutely.

Now, looking at the epidemiology, while the overall rate of HIV diagnosis has gone down nationally, the burden is clearly disproportionate across different populations.

Highlighting the role of social determinants of health.

Profoundly.

We see these deep racial disparities.

African Americans have the largest HIV disease burden of any racial or ethnic group in the US.

The rates of new infection are eight times higher than in whites.

And this is just intrinsically linked to poverty, which limits access to prevention and treatment.

And that's compounded by high levels of stigma, fear, and homophobia in some communities, which prevents open disclosure and adherence.

And the data also reveals a huge concentration of risk based on sexual behavior.

It does.

Male -to -male sexual contact is still the dominant transmission route.

It accounted for nearly 94 % of diagnoses in 2018.

Furthermore,

transgender people, particularly transgender women, face an extremely elevated risk profile.

Data indicates HIV prevalence is nearly 50 times higher in transgender women compared to other adults of reproductive age.

That demands highly targeted, culturally sensitive outreach.

It's the only way.

It's also crucial not to overlook youth.

We see lower viral suppression rates in this group.

Youth are a severe public health concern.

In 2018, 21 % of new HIV diagnoses were among youth, mostly young, gay, and bisexual men.

And they consistently have the lowest rates of viral suppression compared to older groups.

Which means they are both getting infected and struggling to manage the disease effectively.

The barriers are multi -layered, low testing rates, high rates of substance use, which impairs judgment, low rates of consistent condom use, stigma, and critically.

Low rates of pre -fee use.

Very low rates of utilizing pre -fee.

Okay, let's transition to testing.

Which is central to secondary prevention.

You mentioned the standard antibody test, the EIA, confirmed by the Western Blot.

But what about rapid testing and routine screening policy?

Rapid testing has a really revolutionized screening.

We have options like AuraQuick, which uses oral fluid samples.

It's very accurate, right?

It boasts 99 .5 % accuracy and gives you results in 20 minutes.

These rapid self -tests are FDA approved, and they've been vital in overcoming practical barriers.

Like fear of blood draws, or the long wait times with traditional labs.

Exactly.

And what does the CDC recommend for universal screening now?

The policy is very clear.

Routine voluntary HIV testing is recommended for all adults aged 13 to 64 at least once.

And this is often framed as an opt -out policy.

It is.

It's offered unless the patient actively declines.

And for high -risk populations, people with multiple partners, an IDU history, or unprotected sex annual testing is necessary.

This shift to routine testing really reflects the normalization of HIV management.

Nurses also need to understand the practical and ethical distinction between confidential and anonymous testing when they're counseling clients.

That distinction has profound public health implications.

Confidential testing involves reporting the person's name, but that information is strictly protected by state confidentiality laws.

Anonymous testing, on the other hand, assigns a code number and is totally unlinked to the person's name or address.

And the advantage of anonymous testing is that it can increase the willingness of fearful or stigmatized individuals to get tested.

It does.

It eliminates concerns about arrest or discrimination.

But the critical drawback is the follow -up challenge, isn't it?

That's the huge public health disadvantage.

It prevents necessary follow -up for counseling, for treatment initiation, and crucially for partner notification.

All of which are vital secondary prevention strategies.

So community nurses need to explain both options and advocate for the confidential route to ensure that continuity of care.

Whenever possible,

yes.

Shifting to community care.

Since AIDS is managed as a chronic disease today,

a lot of the tertiary prevention happens outside the hospital.

The nurse's role in the community is paramount here.

It transitions from acute care to chronic disease management and case coordination.

They teach families and caregivers about personal care, hygiene, and the consistent application of standard precautions.

For infection control in the home?

And medication adherence to that heart regimen is maybe the single most crucial teaching point.

Why is that consistency so important?

The client has to understand that it's essential not only for their personal health to delay the disease and maintain a high CD4 count, but also as a public health intervention.

Oh, so?

Maintaining consistent adherence drives the viral load down to undetectable levels, and that effectively eliminates the chance of transmitting HIV to others.

So undetectable equals untransmittable.

That is a core counseling message today.

It's empowering for the client and protective for the community.

And clients are protected legally in their daily lives, which is a key part of advocacy.

Yes.

The Americans with Disabilities Act of 1990 is the key legal framework.

It mandates protection for people with HIV AIDS against discrimination in housing, employment, and public situations.

So nurses have to be fierce advocates.

They do.

Implementing non -discriminatory school and work policies, identifying resources like 80 piece, and ensuring confidentiality is strictly maintained.

The goal is to maximize their participation in society.

Because the social benefits of, say, a child attending school far outweigh the practically non -existent risks of transmission in that setting.

Exactly.

Okay, finally, let's look at modern prevention and treatment, specifically pre -exposure prophylaxis or pre -P.

This is genuinely revolutionary.

Pre -P has fundamentally changed the primary prevention landscape.

It's a daily oral pill taken by people who are HIV negative but are at very high risk.

For example, someone with an HIV positive partner or multiple partners or a recent STD.

Right.

And it prevents the virus from establishing itself if they are exposed.

When it's taken daily, studies show it reduces the risk of getting HIV from sex by about 99 percent.

99 percent.

And from injection drug use?

By about 74 percent.

If it's that effective, what are the barriers to compliance, especially among those high -risk youth populations we talked about?

That's where the policy and social challenges really intersect.

The efficacy is excellent, but compliance is difficult.

First, cost and access can be barriers despite assistance programs.

Second, taking a daily pill is a constant reminder of risk, which can be stigmatizing or just challenging for youth who already have low rates of medication adherence in general.

And third, the client has to commit to getting tested every three months for HIV and STDs while on the regimen.

Which is another logistical hurdle.

Are there different options for Pre -P?

Currently, two brands are approved, Truvada and Discovy.

Truvada is recommended for people at risk through sex or injection drug use.

Discovy, however, is restricted in its approval.

It's for preventing HIV through sexual encounters only.

It's not approved for those whose primary risk is receptive vaginal sex or injection drug use.

And the client has to be tested and confirmed negative before starting, and adherence is absolutely non -negotiable for it to work.

Non -negotiable.

And for those who are positive, the standard is anti -retroviral therapy, or RT.

RT is the standard, often involving a fixed -dose combination of three or more drugs.

The therapeutic goal is simple.

Suppress the replication of the retrovirus.

And reduce the viral load to an undetectable level.

Which, as we've said, not only dramatically improves the client's prognosis, but also serves as a powerful public health strategy by reducing community transmission.

Okay, let's move on to sexually transmitted diseases.

The scope of this problem is huge.

I mean, despite decades of awareness campaigns, FTDs are still a major public health challenge in the United States.

They are, and unfortunately, reportable cases just keep increasing across the board, with Chlamydia gonorrhea leading the way.

The rise is alarming, especially with the surge in syphilis and gonorrhea happening at the same time.

It is, and to understand the nursing management, we have to first distinguish between the two main categories based on the pathogen.

This really dictates the treatment and whether a cure is even possible.

And that distinction is bacterial versus viral.

Exactly.

Bacterial STDs, that's gonorrhea, syphilis, and chlamydia, are generally curable with a single course of antibiotics.

But we're facing a severe crisis with antibiotic resistance strains, especially with gonorrhea.

A very severe crisis.

On the other hand, you have viral STDs, genital herpes, or HSV, HPV, HIV, and some forms of hepatitis.

These are chronic infections.

So they require lifetime symptom management, infection control, and ongoing surveillance because there is no true cure.

Correct.

Let's start with gonorrhea, the second most commonly reported notifiable disease.

Gonorrhea rates show these profound demographic disparities.

They spike among males, adolescents, and young adults, and African Americans, where the rate is staggeringly high.

It's 7 .7 times higher than in whites.

The signs and symptoms are often pretty significant in men, puerulent discharge, painful urination, which usually prompts them to get immediate treatment.

But the clinical picture is silent and dangerous for women, which really complicates detection and secondary prevention.

Very dangerous.

In women, it's frequently asymptomatic or so mild that the symptoms are confused with the basic bladder or vaginal infection.

And if treatment isn't sought, the risk is severe.

It is.

Gonorrhea is a major preventable cause of pelvic inflammatory disease, or PID.

And PID, in turn, causes fallopian tube scarring, which leads to long -term consequences like chronic pelvic pain, ectopic pregnancy, and preventable infertility.

And we're facing a truly existential crisis when it comes to treatment for gonorrhea.

It's a critical public health failure story.

It's driven by the pathogen's high mutation rate and poor adherence to past therapies.

Drug resistance is a severe concern because we're running out of effective drugs.

We are.

As recently as 2005, there were five effective treatments.

Now, public health authorities are down to only one remaining recommended dual therapy.

An injection of septriaxone combined with oral azithromycin.

That's it.

And often, this single recommended treatment is administered simultaneously under directly observed therapy, or DOT.

Just like a TB.

Exactly.

Just to ensure the full dose is received, and to minimize the risk of the bacteria evolving resistance to this last effective combination.

And this rise in resistance is a direct consequence of past, indiscriminate use of antibiotics and patient non -adherence.

It is.

Next up, syphilis, caused by treponema pallidum.

The rates have been steadily climbing since 2001 with high co -infection with HIV, especially among men who have sex with men.

Syphilis is known as the great imitator.

It progresses through four stages, which nurses have to be able to recognize to target their intervention.

So, primary syphilis.

Primary syphilis involves a single, usually painless sore called a chancre at the site of entry.

And the chancre typically heals on its own, even without treatment.

And this is where the public health nurse's biggest missed opportunity for tracing often occurs.

Precisely.

Because it's painless and it disappears, the client often thinks the problem has just resolved.

But if it's untreated, it progresses to secondary syphilis.

And that's where the organism is bred through the lymph system.

Right.

Resulting in signs like a non -itchy rash, lymphadenopathy, and just general malaise.

This stage is highly infectious, which makes aggressive contact tracing a critical secondary prevention measure.

And after that, the individual enters latency.

They're asymptomatic, but they still have serological evidence of the disease.

This can last for years.

The final stage is tertiary syphilis, which is rare in the US now because of early antibiotic treatment.

But globally, it's still a serious concern.

It is.

It can lead to blindness, aortic aneurysms, and severe neurological damage.

What's extremely concerning right now is the national increase in congenital syphilis, or CS.

The CS rate has been increasing every single year since 2012, which really reflects a failure of our prenatal secondary prevention and screening.

CS is transmitted from mother to fetus across the placenta.

It is.

And if it's untreated during pregnancy, it can cause stillbirth, blindness, deafness, and profound developmental disabilities in the infant.

And the treatment across all stages is penicillin G.

Yes.

Parentally, barring allergies, it just demonstrates the effectiveness of an older drug when it's used correctly.

Okay.

Finally, let's talk about chlamydia, which you noted is the most common reportable infectious disease,

often called the silent disease.

It earned that name because over 1 .7 million cases were reported in 2018, yet it's asymptomatic in up to 95 % of women and 90 % of men.

And that silence makes secondary prevention incredibly challenging because people are transmitting the infection without knowing it.

Exactly.

And teenage girls and young women are at a particularly high risk because their cervix isn't fully matured, making it more susceptible to infection.

And the complications mean we need aggressive screening policies.

Absolutely.

Like gonorrhea, untreated chlamydia causes PID, ectopic pregnancy, and infertility.

And because it's so prevalent and asymptomatic, the CDC mandates annual chlamydia screening for all sexually active women under the age of 25.

And for high -risk women over 25.

Yeah.

The nursing application is clear.

You have to proactively screen, not wait for symptoms.

You have to.

Now we transition to the chronic viral STDs, starting with genital herpes, caused primarily by HSV2, though we are seeing rising rates of HSV1 causing general infections as well.

And since it's viral, there is no cure.

It's a chronic infection that establishes latency in the sacral nerve of the central nervous system.

The acute signs are painful lesions that start as fluid -filled vesicles and then they ulcerate.

And recurrence is common, often triggered by stress or illness.

It is.

The infectious risk is highest with active lesions, but transmission is possible even when a person is asymptomatic.

Sometimes preceded by that subtle prodromal phase of tingling or itching.

Yes, which makes counseling really complicated.

Why is counseling transmission risk so challenging with HSV compared to, say, chlamydia?

Well, with chlamydia, you treat it and the risk is eliminated.

With HSV, you have to counsel the client on lifelong risk reduction.

They have to understand that transmission is possible even when they feel fine.

Right.

And that they have a legal and ethical responsibility to inform their partners.

Furthermore, HSV2 is strongly linked with an increased risk of acquiring HIV.

And for pregnant women, if they have active lesions at the time of delivery, a C -section is mandatory.

It is.

To prevent a potentially fatal newborn infection from contact with the lesions,

antiviral medications can prevent or shorten outbreaks and reduce the likelihood of transmission to partners.

Okay, finally, human papillomavirus, or HPV, general warts.

The most common STD.

And yet, it's not nationally reportable.

That non -reportable status really masks the scale of this public health crisis.

HPV is pervasive and it's a massive public health issue because two specific high -risk types, HPV16 and HPV18, cause 70 % of all cervical cancer cases.

And it's also linked to vaginal, penile, anal, and oropharyngeal cancers.

It is.

While the warts themselves are usually benign textured, like lesions, it's the oncogenic potential that's the real danger.

And the major intervention here is one of the great successes in modern primary prevention.

Vaccination.

Gardasil 9 is the primary approved vaccine.

The recommended age for vaccination is 11 to 12 years old before potential sexual exposure.

But it can be given up to age 26 for those not previously vaccinated.

It can.

And crucially, nurses have to educate parents and clients on the schedule difference.

It's a two -dose series if you get the first dose before your 15th birthday.

But a three -dose series for those 15 and older, or for certain high -risk groups.

That's a key detail.

But there's a challenge with HPV prevention that doesn't exist with other STDs regarding barrier methods, right?

Yes, this is a key counseling point.

The difficulty is that condoms do not necessarily prevent HPV transmission.

Why not?

Because the warts for the latent virus may grow in areas that standard barriers, like condoms, just don't cover.

So primary prevention relies almost entirely on the early administration of the vaccine.

And for women,

vital regular pap smears for the early detection of pre -cancerous cervical changes caused by HPV.

Okay, our next major segment covers two more critical communicable diseases that demand rigorous population health control.

Viral hepatitis and tuberculosis.

Let's look at the viral hepatitis profiles first.

Yes, emphasizing the differences in transmission, chronic state, and vaccine availability, which is detailed clearly in that reference table.

That comparison table is fundamental for a nurse's assessment.

It is.

Hepatitis A, B, and C all target the liver, causing inflammation, but their routes, their chronicity, and the intervention strategies, they vary drastically.

Let's start with hepatitis A virus, HAV.

Transmitted through the fecal -oral route.

Right, usually via contaminated food or water or direct contact.

It's vaccine preventable, but we've seen an alarming surge in incidences in recent years.

An alarming 850 % increase from 2014 to 2018.

The policy implication there is clear.

This surge is largely associated with outbreaks among people who use drugs and those experiencing homelessness.

So it reflects a failure to manage sanitation and social determinants of health in vulnerable populations.

It does.

HAV is generally a self -limited disease.

It doesn't lead to chronic infection or a lifelong carrier state.

However, children under six often have silent asymptomatic infections.

Which makes the disease go unrecognized and they become a potent source of community infection.

So primary prevention really relies heavily on two pillars.

The vaccine.

Yes, recommended for travelers, MSM, IDUs, and outbreak contacts.

And that's coupled with community -wide sanitation improvements and rigorous personal hygiene education.

Nurses also administer post -exposure immunoglobulin when it's necessary.

Okay.

Shifting to hepatitis B virus, HBV.

HBV is a blood -borne pathogen transmitted through blood, semen, sexual contact, and perinatally from mother to child.

It is also vaccine -preventable, which is why overall incidence has been decreasing dramatically in vaccinated populations.

And there's a crucial clinical distinction here from HIV regarding the virus's hardiness.

A very important one.

HBV can survive for at least one week dried at room temperature on environmental surfaces.

Wow.

That significantly increases the risk for transmission in health care settings or where blood spills occur.

It mandates rigorous infection control.

This hardiness increases infectivity risk, making meticulous cleaning and decontamination absolutely critical in any setting where blood exposure is possible.

Nurses must be hypervigilant about standard precautions.

And what are the long -term outcomes of an HBV infection?

An acute infection resolves in most adults and they get lifelong immunity.

However, chronic HBV infection occurs in about 5 % of infected adults and up to 90 % of infected infants.

And these chronic carriers are at extremely high risk for life -threatening complications.

Including liver cancer or hepatocellular carcinoma and cirrhosis.

Because of the occupational exposure risk, OSHA mandates that employers offer the HBV vaccine at the employer's expense to all health care workers with potential exposure to blood or body fluids.

And the third major type, hepatitis C virus.

HCV, which has become a focus of major treatment breakthroughs.

HCV is primarily blood -borne.

While historically it was linked to pre -1992 blood transfusions,

today the highest risk comes almost entirely from sharing needles or equipment used to inject drugs.

And unlike A and B, there is currently no vaccine available for HCV.

That's right.

So prevention has to focus on screening and risk reduction and now modern treatment.

An acute hepatitis C infection is short -term,

but 75 to 85 % of those infected develop chronic lifelong infection.

And historically that led to cirrhosis, liver cancer, and death.

But the good news is the Revolutionary Direct Acting Antiviral, or DAA,

medications, they have a cure rate of over 95%.

Which has transformed HCV from a terminal chronic disease into a highly curable one.

It has.

So the nursing application is to ensure that clients are screened, especially high -risk individuals and those born between 1945 and 1965,

and then successfully case managed into this highly effective treatment.

Our final major infectious risk is tuberculosis, or TB, caused by mycobacterium tuberculosis.

This remains one of the top 10 causes of death worldwide, presenting a constant public health control challenge.

The global burden is truly staggering.

10 million people contracted it in 2018.

Transmission occurs through airborne droplets when a person with active pulmonary TB talks, coughs, or sneezes.

And the symptoms we teach clients to watch for are a persistent cough lasting over three weeks, chest pain.

And those classic constitutional symptoms like unexplained weight loss, fever, night sweats, and fatigue.

And we have to talk about the silent global threat, latent TB infection, or LTBI.

This is critical for population health nurses.

An estimated one -fourth of the world's population has latent TB.

And these individuals are infected with the bacteria but are asymptomatic, not yet ill, and cannot transmit the disease.

But the risk of reactivation to active TB is high for immunocompromised persons, substance abusers, and, critically, for people who are HIV positive, where the outcome is typically fatal if untreated.

So LTBI has to be identified and treated to prevent future active cases.

It's a core secondary prevention strategy.

And the major challenge worldwide is drug resistance, which you framed as a policy crisis caused by non -adherence.

It is a global public health crisis.

And it largely stems from poor adherence to the long, difficult, and sometimes toxic treatment regimens.

We define multidrug -resistant TB, MDRTB, as resistance to the two most effective first -line drugs.

Rifampin and isoniazid.

Right.

And even more alarming is extremely drug -resistant TB, XDRTB, which is MDRTB plus resistance to

at least three injectable second -line drugs.

And preventing poor adherence through robust case management is the single most important action to prevent this resistance from spreading.

It is the only way.

So how do nurses manage diagnosis and screening, given the difference between latent and active infection?

The most common initial screening tool is the MANTU tuberculin skin test, or TST, using purified protein derivative, or PPD.

This involves injecting 0 .1 milliliters of PPD intradermally.

And the reaction has to be read by a trained professional 48 to 72 hours later.

And this is where the analytic assessment skill of the public health nurse really comes in, because the interpretation of the result changes entirely based on the client's risk factors.

Absolutely.

We measure only the in -duration that raised hardened area in millimeters, and the clinical decision -making is tiered.

So for the most immunocompromised clients, like those with HIV or those receiving immunosuppressive therapy.

A positive result is only greater than or equal to 5 millimeters of in -duration.

That's a very low threshold, because their immune response is compromised and may not mount a stronger reaction.

And for intermediate risk groups.

For high -risk individuals, like foreign -born persons from endemic areas, IV drug users if they're HIV negative, or residents and employees of long -term care facilities, the threshold increases to greater than or equal to 10 millimeters.

And only for low -risk persons with no known risk factors is the threshold greater than or equal to 15 millimeters.

Correct.

And understanding these tiers is absolutely essential for secondary prevention protocols.

We also have the newer alternative to the TST, the blood test.

Yes.

The interferon gamma release assay, or IGRA blood test, sometimes called quantiferon TB, is increasingly used.

It's not subject to issues like false positives from past BCG vaccinations or false negatives due to severe immunosuppression.

So it's a more specific tool, especially for high -risk populations.

It is.

But ultimately, the diagnosis of active TB is confirmed by culturing the tubercle bacilli from sputum.

This brings us to the core of nursing practice in communicable disease control.

From risk assessment and complex treatment adherence, the nurse is the critical link.

Functioning as a counselor, educator, advocate, case manager, and primary care coordinator across the three essential levels of prevention.

The framework for intervention is primary, secondary, and tertiary prevention, which aligns perfectly with population health concepts.

It allows us to intervene at every stage of the disease process, both for the individual and for the community.

Let's start with primary prevention averting the onset of disease.

This begins and ends with risk assessment, specifically obtaining a sexual and injection drug use history.

The ability to get an accurate, detailed sexual and IDU history is the critical entry point for prevention.

This is sensitive information, but it is necessary for appropriate testing, treatment decisions, and subsequent partner notification.

So nurses who are uncomfortable discussing topics like sexual behavior, orientation, or drug use will be fundamentally ineffective in this role.

They will.

So how should a nurse approach this history -taking to overcome client defensiveness and their own discomfort?

They have to be open, non -judgmental, and use direct, simple, and explicit language to describe specific behaviors.

Avoid making assumptions based on the client's sex, age, or appearance.

So instead of assuming, you ask directly.

You ask directly.

How many sex or drug partners have you had over the past six months, or what kind of protection do you use most often?

This open communication models candor and facilitates honesty, which is necessary for accurate risk stratification.

We also need to ask specific questions about sexual practices, not just partner numbers, because some routes are higher risk.

Yes.

Practices like unprotected anal or vaginal intercourse carry the highest risks for HIV and STDs.

And crucially, clients who engage in genital anal or oral anal contact will require throat and rectal cultures for certain STDs.

Like gonorrhea and chlamydia.

In addition to the standard genital cultures, if you don't ask about the specific sites of exposure, you will miss a significant number of infectious cases and fail to contain the spread.

And we have to link the use of drugs and alcohol directly to increased infectious risk.

You must.

Drug and alcohol use directly increases risk because it lowers inhibitions and pairs judgment, making clients far more likely to engage in unprotected sex or to forget safer sex protocols.

And addiction may drive vulnerable individuals to acquire drugs or money through transactional sexual favors.

Which exponentially increases both the frequency of contacts and the risk of contracting STDs.

Intervention here requires a dual focus.

Substance abuse treatment alongside STD education.

Once the assessment is complete, the nurse moves to counseling and behavioral intervention, starting with safer sex practices.

And while sexual abstinence is the best and most effective way to prevent STDs, it's often not a realistic or achievable goal for many clients.

So the nurse has to teach specific, realistic, safer sex behaviors.

Including masturbation, dry kissing, and the consistent and correct use of barrier protection.

Condoms are highly effective if they're used correctly and consistently because they prevent the exchange of body fluids.

Now, what about barrier options for individuals with latex sensitivities or those who prefer a female -controlled option?

The female condom, like the FC2, provides an excellent barrier and is a key alternative, especially for a client with a latex sensitivity as it's made of polyurethane.

And the main advantage is that its use is controlled by the user.

Which offers empowerment and prevention.

The nurse has to counsel on proper use and disposal of these options.

And for injection drug use intervention, which is a major driver of HIV and HIV today.

The primary prevention message is unequivocal.

Advise against using injectable drugs.

And if the client continues to use, advise against sharing needles, syringes, or any drug paraphernalia.

Effective outreach programs are key here.

They are.

Involving community peers who can access hard -to -reach groups, increasing the accessibility of drug treatment programs combined with HIV testing and counseling.

And importantly, implementing harm reduction strategies.

Like sterile needle and syringe exchange programs.

Exactly.

Moving on to secondary prevention early detection and follow -up.

This revolves around mass screening policies.

The CDC recommendation for routine voluntary or opt -out HIV testing for all adults ages 13 to 64 is the flagship secondary prevention strategy.

Nurses must identify characteristics of high -risk clients.

IDU history, multiple partners, unprotected sex.

And ensure they receive annual testing, because early detection allows for immediate treatment, viral suppression, prophylactic therapy, and mandatory risk reduction education.

And if a client tests positive for a reportable STD, the next step is the crucial population level strategy of partner notification or contact tracing.

Partner notification is a core function of public health nursing.

The index case, the person diagnosed, is asked to confidentially provide the names of all recent partners.

And the public health nurse, operating under strict legal authority,

then contacts those partners to offer counseling, testing, and treatment.

And this is a delicate process where confidentiality is paramount, but public safety is the ultimate goal.

Absolutely.

The identity of the index case is never revealed to the partners.

Or the entire system collapses due to fear of disclosure.

The nurse's role is solely to inform the exposed individuals of their risk so they can seek evaluation and treatment.

This process is used not just for STDs, but also for highly infectious diseases like TB and HAV.

And we saw during recent large -scale infectious outbreaks like COVID -19, how difficult effective tracing became when people didn't know or couldn't recall their contacts.

It just underscores the necessity of a functioning public health infrastructure.

Finally, we reached tertiary prevention,

managing chronic illness and preventing complications.

This is particularly relevant for viral STDs and TB, where compliance is essential.

For viral STDs like HIV or herpes, tertiary care focuses intensely on symptom management and psychosocial support.

Many clients report profound feelings of contamination, guilt, or low self -worth.

So connecting them with support groups and mental health resources is vitally coping with the chronicity of the disease.

It is.

And the most important population -level tertiary strategy to prevent the ultimate complication drug resistance is directly observed therapy.

Or DOT.

DOT is primarily used for TB treatment, where regimens are long, often six to nine months, and adherence is frequently poor.

So the nurse observes and documents the client taking their medication, often through scheduled home visits or health department appointments.

This ensures effective individual treatment and, critically, protects the community from the emergence and spread of highly dangerous antibiotic -resistant strains like MDRTB and XDRTB.

It is a non -negotiable public health strategy.

And we must mention the importance of teaching standard precautions in the home setting, especially for HIV clients.

This is fundamental case management.

Nurses teach caregivers and family members to treat all blood and body fluids as potentially infectious.

This includes instructing them on the proper use and disposal of protective equipment gloves, masks, gowns, and the crucial technique of rigorous hand washing.

And effective case management for HIV clients in tertiary care is also vital to secure necessary resources.

Especially financial funding through ADAPS for heart medications and ongoing support services, which maximizes their lifespan and suppresses their viral load.

This has been a truly comprehensive deep dive into the risks and population health management strategies for communicable diseases.

Before we wrap up, let's quickly consolidate the most important practice takeaways for our listeners.

First, remember this.

Most of the communicable diseases we discussed, HIV, STDs, HV, HBV, are largely preventable.

Because their transmission routes are known, and often directly behavior -related.

Right.

So nursing interventions are highly effective when they're focused on altering these high -risk behaviors or providing community immunization.

Second, STDs are a massive public health problem with severe long -term complications.

The link between viral STDs like HPV, HIV, and HSV, and the development of various cancers, means that screening and vaccination are, quite literally, life -saving prevention methods.

Third, never forget the social determinants of health.

The key risk factors, being younger than 25, minority status, urban setting, poverty, and substance use all, correlate with higher incidence rates.

Community health nurses must target these populations with resources, not just clinical treatment.

And perhaps the most crucial clinical takeaway.

Many STDs, particularly chlamydia and gonorrhea in women, are silent and asymptomatic.

Which necessitates proactive secondary prevention through rigorous screening, like mandatory annual chlamydia testing for sexually active women under 25.

Because early detection prevents progression, complications, and further community transmission.

Finally, we cannot overstate the public health policy value of interventions like partner notification or contact tracing for diseases like TB, HAV, and STDs.

And direct observed therapy, or DOT, remains the essential tertiary strategy for enforcing treatment adherence for TB, protecting the community from resistance and maintaining the effectiveness of our precious antibiotic supply.

And here's where it gets really interesting.

As we look to the future of public health nursing and how we assess risk, we noted earlier the findings of studies regarding HIV -infected Latino men, which showed that self -identified,

identity -straight, gay bisexual doesn't always align with actual risk behavior.

Right.

Who is sharing needles or engaging in unprotected sex?

That study found that men who identified as straight sometimes engaged in risky IV drug use or needle sharing at rates that equaled or even exceeded those of gay or bisexual men in the same sample.

And this complexity fundamentally challenges the assumptions we might bring to the bedside.

It does.

So what does this all mean for the practicing community health nurse engaging in that initial crucial risk assessment?

Given the complexity of sexual behavior and the continuous challenge of disclosure, or a client's actual risk profile is not always visible through their self -identified orientation or appearance, how can community health nurses evolve their history -taking and targeted outreach strategies to ensure no high -risk population is missed due to assumptions, bias, or discomfort during that foundational primary prevention interview?

That is the core challenge of practicing population health moving forward.

A profound and necessary crutching for critical reflection.

Thank you for joining us on this deep dive into communicable disease risks and the vital role of the community health nurse.

We are proud to bring you this expert analysis.

Stay informed, look beyond the symptoms, and stay healthy.

And from all of us here on the Last Minute Laser team, thank you for listening.